|
||
Ultiblast Pregnancy |
||
Incomplete transplacental transfer of Ultiblast was found using an ex vivo human perfusion model (Hnat 2005).
Information related to the use of Ultiblast in pregnancy is limited (Yoshida 2013).
A mother was treated with 1 g IV every 8 hours for 7 days while her newborn was exclusively breastfed. Five samples of hindmilk were collected and the average breast milk level was 480 mcg/L. Estimated average and maximum infant intake were 71 mcg/kg/day (0.13% of weight-adjusted maternal dose) and 97 mcg/kg/day (0.18% of weight-adjusted maternal dose), respectively. When asked later, the mother stated her infant had no symptoms of oral thrush, watery diarrhea, or diaper dermatitis requiring antifungal therapy during therapy or during the month after therapy.
AU: Use is not recommended unless the benefit outweighs the risk to the infant. UK: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. US: Caution is recommended. Excreted into human milk: Yes Comments: -This drug is not expected to cause harmful effects in the nursing infant. -Clinical monitoring of infants for altered gastrointestinal flora has been suggested; loose bowel movement may occur in the nursing infant. -This drug is considered compatible with breastfeeding according to the Therapeutic Guidelines Antibiotic Edition, version 14.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|